Details van artikel 177 van 409 gevonden artikelen
MO56-1 Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Titel:
MO56-1 Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)